ACQUISITION OF CYTOGENETIC ABNORMALITIES IN PATIENTS WITH IPSS LOW AND INTERMEDIATE-1 RISK. STUDY FROM THE SPANISH GROUP OF MYELODYSPLASTIC SYNDROME

被引：0
|
作者：
Merchan, B. [1 ]
Ortega, M. [2 ]
Llamas-Poyato, M. J. [3 ]
Cortes, M. [4 ]
Arnan, M. [5 ]
Cervero, C. [6 ]
Montoro, J. [1 ]
Gimenez, T. [7 ]
Lopez, M. [8 ]
Arenillas, L. [9 ]
Valcarcel, D. [1 ]
机构：
[1] Hosp Valle De Hebron, Hematol, Barcelona, Spain
[2] Hosp Valle De Hebron, Hematol Cytogenet Lab, Barcelona, Spain
[3] Hosp Reina Sofia, Hematol, Cordoba, Spain
[4] Fundacio Hosp Asil, Hematol, Granollers, Spain
[5] Inst Catala Oncol Duran & Reynals, Hematol, Barcelona, Spain
[6] Hosp Virgen de la Luz, Hematol, Cuenca, Spain
[7] Hosp Joan XXIII Tarragona, Hematol, Tarragona, Spain
[8] Hosp Univ La Fe, Hematol, Valencia, Spain
[9] Hosp del Mar, Hematol Cytol Lab, Barcelona, Spain
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
10.1016/S0145-2126(15)30272-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
271
引用
收藏
页码：S136 / S136
页数：1
相关论文
共 50 条
  • [41] Identification Of Chromosomal Abnormalities By Microarray-Based Genomic Profiling As Compared To Karyotyping In Patients With Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group
    Stevens-Kroef, Marian J. P. L.
    Simons, Annet
    El Idrissi-Zaynoun, Najat
    van der Reijden, Bert A.
    Cremers, Eline M. P.
    Alhan, Canan
    Westers, Theresia M.
    Wisselaar, Heleen A. Visser
    Chitu, Dana
    Vellenga, Edo
    Klein, S. K.
    Wijermans, Pierre W.
    De Greef, Georgine E.
    Schaafsma, Martyn R.
    Kooy, M. van Marwijk
    Muus, Petra
    Ossenkoppele, Gert J.
    van de Loosdrecht, Arjan A.
    Jansen, Joop H.
    [J]. BLOOD, 2013, 122 (21)
  • [42] ACE-536 INCREASES HEMOGLOBIN LEVELS IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY
    Platzbecker, U.
    Germing, U.
    Giagounidis, A.
    Goetze, K.
    Kiewe, P.
    Mayer, K.
    Ottmann, O.
    Radsak, M.
    Wolff, T.
    Hankin, M.
    Wilson, D.
    Sherman, M.
    Attie, K.
    [J]. HAEMATOLOGICA, 2014, 99 : 500 - 500
  • [43] T cell mediated autologous cytotoxicity against hematopoietic precursor cells in low and intermediate-1 risk Myelodysplastic syndrome.
    Chamuleau, Martine E. D.
    Westers, Theresia M.
    van Dreunen, Linda
    Groenland, Judith
    Zevenbergen, Adri
    Eeltink, Corien
    Ossenkoppele, Gert J.
    de Loosdrecht, Arjan A. Van
    [J]. BLOOD, 2007, 110 (11) : 223B - 223B
  • [44] Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial
    Oliva, Esther Natalie
    Santini, Valeria
    Alati, Caterina
    Poloni, Antonella
    Molteni, Alfredo
    Niscola, Pasquale
    Sanpaolo, Grazia
    Salvi, Flavia
    Palumbo, Giuseppe A.
    Balleari, Enrico
    Impera, Stefana
    Cortelezzi, Agostino
    Liberati, Anna Marina
    Avanzini, Paolo
    Di Bartolomeo, Paolo
    Rose, Christian
    Beyne-Rauzy, Odile
    Buccisano, Francesco
    Bocchia, Monica
    Morabito, Fortunato
    Stamatoullas, Aspasia
    Ronco, Francesca
    Zini, Gina
    D'Errigo, Maria Grazia
    Ranieri, Natale
    Cufari, Patrizia
    Santacaterina, Irene
    Fenaux, Pierre
    Latagliata, Roberto
    [J]. BLOOD, 2015, 126 (23)
  • [45] LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY
    Platzbecker, U.
    Germing, U.
    Giagounidis, A.
    Goetze, K.
    Kiewe, P.
    Mayer, K.
    Ottmann, O.
    Radsak, M.
    Wolff, T.
    Haase, D.
    Hankin, M.
    Wilson, D.
    Zhang, X.
    Laadem, A.
    Sherman, M.
    Attie, K.
    [J]. LEUKEMIA RESEARCH, 2015, 39 : S25 - S25
  • [46] THE ADDITION OF COMORBIDITY ALLOWS A BETTER STRATIFICATION AND DEVELOPMENT OF A SPECIFIC PROGNOSTIC SCORE IN THE GROUP OF PATIENTS WITH MYELODYSPLASTIC SYNDROME OF LOW RISK BY IPSS
    Knight Asorey, T.
    Falantes, J. F.
    Calderon-Cabrera, C.
    Marquez-Malaver, F. J.
    Bernal, R.
    Espigado, I
    Perez-Simon, J. A.
    [J]. HAEMATOLOGICA, 2015, 100 : 186 - 187
  • [47] Assessment of two doses of infliximab in patients with low/intermediate risk IPSS myelodysplastic syndrome (MDS): An EORTC leukemia group (LG) randomized phase II trial (06023)
    Baila, Liliana
    Suciu, Stefan
    Muus, Petra
    Amadori, Sergio
    Delforge, Michel
    Ossenkoppele, Gert
    Selleslag, Dominik L. D.
    Thyss, Antoine
    Demuynk, Hilde
    Gadisseur, Alain
    Vermeulen, P.
    De Boer, Carla
    Zwierzina, Heinz
    De Witte, T. M.
    [J]. BLOOD, 2007, 110 (11) : 436A - 436A
  • [48] Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
    Azra Raza
    Naomi Galili
    Deborah Mulford
    Scott E Smith
    Gail L Brown
    David P Steensma
    Roger M Lyons
    Ralph Boccia
    Mikkael A Sekeres
    Guillermo Garcia-Manero
    Ruben A Mesa
    [J]. Journal of Hematology & Oncology, 5
  • [49] Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"
    Sebert, Marie
    Chaffaut, Cendrine
    Thepot, Sylvain
    Orvain, Corentin
    Cluzeau, Thomas
    Loschi, Michael
    Peterlin, Pierre
    Chevallier, Patrice
    d'Aveni, Maud
    Rubio, Marie-Therese
    Rauzy, Odile Beyne
    Huynh, Anne
    Charbonnier, Amandine
    Fegueux, Nathalie
    Fossard, Gaelle
    N'guyen-Quoc, Stephanie
    Park, Sophie
    Sapena, Rosa
    Chermat, Fatiha
    Ades, Lionel
    Chevret, Sylvie
    Fenaux, Pierre
    Robin, Marie
    [J]. BLOOD, 2021, 138 : 1842 - +
  • [50] Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κB Activation
    Randhawa, Jasleen K.
    Jabbar, Kausar Jabeen
    Kadia, Tapan
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Hearn, Katherine
    Bueso-Ramos, Carlos E.
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2014, 124 (21)
12345